BioSpace News Archive

The nine-month project is a collaboration between Southern Water, Microvi, WesTech Engineering, Inc., and the University of Portsmouth.

3D Systems (NYSE: DDD), the originator of 3D printing, has been selected as a 2018 recipient of the Cellerant Best of Class Technology Award for its NextDentTM 5100.

According to a report from Hexa Research, the U.S. medical cannabis market is expected to grow from USD 5.44 Billion to reach USD 19.48 Billion by 2024.

On the occasion of the 73rd Session of the United Nations General Assembly (UNGA 73), Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful development of the ‘Augmented Infant Resuscitator (AIR)’ - an add-on device for conventional neonatal bag-valve-mask (BVM) resuscitators that helps caregivers to effectively resuscitate asphyxiated newborn babies

ChiroFusion, the leading cloud-based electronic medical record (EMR) software for chiropractors, has released a new integrated review and reputation management platform that automates the process of review acquisition and online reputation monitoring.

THE COMPANY PREPARES FOR TARGETED COMPLETION OF THE REGIONAL MARKET SALES FORCE IN 2019

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the presentation and publication of two clinical cases demonstrating proof-of-concept for BLU-667 in combination with osimertinib (Tagrisso®) in treatment-resistant, EGFR-mutant non-small cell lung cancer

RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will present a poster entitled, “The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity,” at the 16th Annual Discovery on Target Conference.

fter 100 days of action, DHHS Secretary Alex M. Azar released a report on the early results of the American Patient First Blueprint. The report reiterates the Administration’s call for greater competition in the pharmaceutical marketplace to address rising drug prices and reduce out-of-pocket costs.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (“Actinium” or “the Company”), will introduce its next generation targeted lymphodepletion technology for CAR-T therapy on a conference call and webcast today at 4:15 PM ET. Actinium’s next generation targeted lymphodepletion technology is intended to offer a universal solution to certain key challenges facing the CAR-T industry.